SCHEMBL24491200

SCHEMBL24491200

CCC(C)(C)c1cn(CCOCCOCCOCCOCCOCCNC(=O)COCC(=O)Nc2ccc(COC(=O)C(C)(C)C)cc2)nn1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ CA12 O43570 4/20 0.33
▸ CA1 P00915 4/20 0.33
▸ CA2 P00918 4/20 0.33
▸ CA4 P22748 4/20 0.33
▸ CA9 Q16790 4/20 0.33
▸ CA14 Q9ULX7 4/20 0.33
▸ NAMPT P43490 2/20 0.33
▸ GBA1 P04062 1/20 0.33
▸ RAB9A P51151 3/20 0.32
▸ MAPK14 Q16539 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ ALDH1A1 P00352 3/20 0.32
▸ GLA P06280 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24491154 0.94 FOLH1 (0.38) FOLH1MAPK1CA12CA1CA2
SCHEMBL22299956 0.86 FOLH1 (0.38) FOLH1MAPK1CA12CA1CA2
SCHEMBL24491129 0.80 FOLH1 (0.35) FOLH1
SCHEMBL23974072 0.77 FOLH1 (0.41) FOLH1MAPK1CA12CA1CA2
SCHEMBL23974353 0.76 FOLH1 (0.43) FOLH1MAPK1CA12CA1CA2
SCHEMBL24491155 0.74 OPRM1 (0.37) FOLH1CA12CA1CA2CA9
SCHEMBL24491189 0.73 OPRM1 (0.38) FOLH1
SCHEMBL15132969 0.65 KMT2A (0.38) NAMPTGBA1GAAKMT2A
SCHEMBL19500399 0.65 ALDH1A1 (0.40) CA12CA1CA2CA9ALDH1A1
SCHEMBL22300339 0.65 GBA1 (0.36) FOLH1GBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220175761-A1 BI-LIGAND DRUG CONJUGATE AND USE THEREOF COHERENT BIOPHARMA SUZHOU LTD (CN) 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220175761-A1 BI-LIGAND DRUG CONJUGATE AND USE THEREOF SLC10A1, CD47, SELPLG FOLH1 234/4885MAPK1 3577/4885CA12 432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback